Filing Details

Accession Number:
0001209191-19-054503
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-10-30 16:16:51
Reporting Period:
2019-10-28
Accepted Time:
2019-10-30 16:16:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1510487 Principia Biopharma Inc. PRNB Pharmaceutical Preparations (2834) 263487603
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1752139 J. Daniel Becker C/O Principia Biopharma Inc.
220 E. Grand Avenue
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-10-28 68,404 $33.41 603,404 No 4 P Indirect See Footnote
Common Stock Acquisiton 2019-10-29 9,196 $33.98 612,600 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Footnotes
  1. Price represents the weighted average price of the shares purchased. The purchase price ranged from $32.66 to $33.65 per share. Upon request by the Commission staff, the Issuer or the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  2. The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.
  3. Price represents the weighted average price of the shares purchased. The purchase price ranged from $33.50 to $34.00 per share. Upon request by the Commission staff, the Issuer or the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.